Post by The Lancet Infectious Diseases

🔥The Lancet Infectious Diseases’ March 2026 Issue is live now! 📊 This month’s issue features an article by Jonathan Mosser and colleagues of the estimates of Chagas disease deaths, years of life lost (YLLs), prevalence, incidence, years lived with disability (YLDs), and disability-adjusted life-years (DALYs) for 204 countries and territories by age and sex. 💡 These updated estimates show decreasing prevalence and incidence in endemic countries, highlighting the importance of socioeconomic development, housing conditions, and vector-control policies. The increase in prevalence in non-endemic countries requires new strategies for screening, early recognition, and access to care in these settings. Also, the shift in age distribution highlights the importance of preparing and funding health systems for caring for older populations with advanced sequelae. Also in this month’s issue: 🔹EDITORIAL: Promises and challenges of AI in infectious diseases 🔹 A test-negative design study on vaccine effectiveness of a bivalent respiratory syncytial virus (RSV) pre-F vaccine against RSV-associated hospitalisation among adults aged 75–79 years in England 🔹A superiority, open-label, randomised, controlled trial (VICTOR-CPA trial):  Oral itraconazole versus oral voriconazole for treatment-naïve subjects with chronic pulmonary aspergillosis in India 🔹 A phase 1 randomised, placebo-controlled, dose-escalation clinical trial on the safety, tolerability, and immunogenicity of the ChAdOx1RVF vaccine against Rift Valley fever among healthy adults in Uganda 🔹 An updated global systematic review and meta-analysis on the complications and mortality of typhoid disease 🔹 Three paper (review) Series on AI and infectious diseases Read more exciting content in the present issue here: bit.ly/3N5mqBx Alt: Cover of The Lancet Infectious Diseases’ March 2026 issue by Daria Lada- Global, regional, and national burden of Chagas disease, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 #RSV-preF vaccine, #elderly, #itraconazole, #chronic pulmonary aspergillosis, #antibiotic treatment duration, #bloodstream infection, #mpox, #diagnostics, #typhoid, #Chagas disease, #Rift Valley fever, #Lyme Borreliosis, #vaccine, #community-acquired respiratory virus infections, #immunocompromised, #artificial intelligence, #AMR, #toe osteomyelitis Rebecca Symes, Inderpaul Singh Sehgal, Sean W. X. Ong, Deborah Williamson, John A Crump, Zacchaeus Anywaine, Susanne Eder-Lingelbach, Hans H Hirsch, Alex Howard, Jesus Rodriguez Manzano, Anna Odone, MD MSc MPH, Dr. Rebecca Thombre